National Research Institute-Huntington Park

Huntington Park, California 90255

0 studies enrolling now · 17 studies all time

What they study most

Dyslipidemias, High Cholesterol, Hypercholesterolemia, Hypertension, NASH - Nonalcoholic Steatohepatitis, Non Alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Obesity, Overweight, Pregnancy, T2D

Studies at this site

• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
• A Phase 2b Study of Icosabutate in Fatty Liver Disease — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Randomized Study of Obicetrapib as an Adjunct to Statin Therapy — Completed
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
• A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin — Completed
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics — Completed
• A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes — Completed
• Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects — Completed
• Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test — Completed